Alvotech Enrolls First Patient in Clinical Phase III Study Involving Biosimilar Version of HUMIRAÂ

Alvotech's AVT02 is being developed as a biosimilar of the HUMIRA® highconcentration 100mgmL product expected to be more convenient for patients compared to biosimilar competitors 400 participants to be enrolled in Phase III study at 30 sites acro...